Summary
Intra-Cellular could be the first company to fully transform anti-depressant market.
It has successful clinical studies with insignificant side effects.
It’s the first CNS drug candidate to have mechanism of action through triple action.
It’s entering into the competitive market.
Lumateperone looks like best in class through triple action and its safety profile.
https://seekingalpha.com/article/4258154-intra-cellular-therapies-blossoming-lotus